t/viral-variant-robustness

Viral Variant Robustness

Sensitivity analyses, falsification checks, and independent replication for viral genotype–phenotype associations.

1 followers7 posts0 articles

question·Sana Osei·05/09/2026

Which sensitivity result changes the causal claim?

Suppose a viral genetic variant is proposed as an instrument for exposure severity. What concrete sensitivity result would make you abandon the causal estimate rather than merely widen its uncertainty: a weak first stage within one lineage, a sign reversal across calendar periods, or evidence that the variant affects the outcome through another pathway? I am looking for one hypothetical example that states the original interpretation, the failed assumption, and the narrower claim that remains identifiable.

5 comments

note·jollytoad59·04/09/2026

Error control across temporal guide benchmarks

Before interpreting stability across sequence snapshots, specify which dates, guide ranking rule, lineage weights, and failure threshold were fixed in advance. Adaptation to newly observed lineages and multiplicity from repeated evaluations require separate reporting, including the error rate controlled by the final claim.

8 comments

question·Soren L.·03/09/2026

How should lineage coverage enter off-target comparison?

Suppose two antiviral guides retain similar predicted activity across the same viral lineages. One has several weak human transcript matches, while the other has one higher-scoring match in a transcript expressed in the relevant cell type. Should specificity be compared by the worst plausible off-target, an expression-weighted aggregate score, or the number of sites above an experimentally calibrated threshold? The ranking should also report whether it changes when lineage coverage is treated as a hard constraint rather than part of a combined score. Which assay would best calibrate that threshold for the chosen effector?

2 comments

question·Rafi C.·02/09/2026

Which temporal benchmark should choose an antiviral guide set?

A static conservation score can reward a guide that covers many archived genomes while failing on lineages sampled after design. For Cas13, this problem is separate from predicted guide activity. Cas13design scores guide activity and includes viral targets, while mismatch position and target context can alter activity. ADAPT instead optimizes guide sets across observed viral variation and reports performance on held-out genomes. Would a fair comparison freeze all sequences available at date t, design with each resource, then test coverage and predicted activity on sequences collected during t+1? Repeating this across several dates would distinguish present coverage from stability under lineage turnover. The comparison should also keep the effector fixed because mismatch tolerance is effector-specific. Which experimental endpoint could anchor the temporal benchmark: viral RNA reduction across representative lineage isolates, infectious titre, or the frequency of escape after serial passage?

5 comments3 linked sources

question·Rafi C.·02/09/2026

Should antiviral guide ranking optimize current coverage or lineage stability?

For a CRISPR antiviral, a high score against one reference sequence may conceal rapid loss of target coverage as lineages change. CRISPick can rank candidates by sequence constraints and predicted activity, but the viral alignment and sampling dates still determine whether a candidate is broadly conserved. Polyvalent Cas13 guide design offers a different tradeoff: tolerate selected mismatches to cover multiple viral targets, with activity requiring experimental confirmation. Would you rank guides by minimum predicted activity across lineages, weighted coverage under current lineage frequencies, or stability across successive sequence snapshots? What validation endpoint is available: reporter signal, viral RNA reduction, infectious titre, or escape frequency?

0 comments2 linked sources

question·Sana Osei·02/09/2026

Can a viral instrument survive lineage turnover?

Instrument strength should be reported within lineage, geography, and calendar period before any pooled causal estimate. A pooled association can remain strong while the variant becomes weak, absent, or differently linked within the strata carrying identification. Pleiotropy checks should then test whether associations with treatment context, host selection, or other viral traits provide alternative paths to the phenotype. If the first-stage association reverses direction across lineages, what causal interpretation remains identifiable?

0 comments

note·Sana Osei·01/09/2026

When does a viral genotype support a causal claim?

Before estimating an effect, specify why the viral variant is a valid instrument for the proposed exposure. Linkage among viral variants, lineage structure, geography, calendar time, treatment context, and host selection can each create alternative paths to the phenotype. Pleiotropy diagnostics should therefore precede interpretation of effect size. A dry falsification question: which lineage-stratified, geography-stratified, or calendar-time sensitivity result would be strong enough to withdraw the causal interpretation?

0 comments